UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1092-13
Program Prior Authorization/Notification
Medication Selzentry® (maraviroc)
P&T Approval Date 1/2012, 2/2013, 11/2013, 2/2015, 2/2016, 2/2017, 2/2018, 2/2019, 2/2020,
2/2021, 1/2022, 1/2023, 1/2024, 1/2025
Effective Date 4/1/2025
1. Background:
Selzentry® (maraviroc) is a CCR5 co-receptor antagonist indicated in combination with other
antiretroviral agents for the treatment of only CCR5-tropic human immunodeficiency virus type 1
(HIV-1) infection in adults and pediatric patients weighing at least 2 kg. Selzentry is not
recommended in patients with dual/mixed- or CXCR4-tropic HIV-1. Tropism testing with a
highly sensitive tropism assay is required for the appropriate use of Selzentry. 1
Members will be required to meet the coverage criteria below.
2. Coverage Criteriaa:
A. Authorization
1. Selzentry will be approved based on both of the following criteria:
a. Patient has CCR5-tropic HIV-1 infection as confirmed by a highly sensitive tropism
assay
-AND-
b. Patient is currently taking or will be prescribed an optimized background antiretroviral
therapy regimen
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Selzentry [Package Insert]. Research Triangle Park, NC: ViiV Healthcare; September 2022.
© 2025 UnitedHealthcare Services, Inc.
1
Program Prior Authorization/Notification - Selzentry (maraviroc)
Change Control
11/2013 Annual Review - Removed reauthorization criteria. Clinical intent is to validate
tropism assay testing at time of therapy initiation. Updated additional clinical rules.
Updated references. Added change control table.
2/2015 Removed safety information in background section and added updated label
language. Updated references.
2/2016 Annual review. Updated background section to reflect most current label. Removed
reference to tropism testing from the DHHS treatment guidelines. Revised duration
of authorization.
2/2017 Annual Review. Updated background information to reflect most current label.
Updated reference.
2/2018 Annual review. No changes to coverage criteria.
12/2018 Administrative change to add statement regarding use of automated processes.
2/2019 Annual review. No changes to coverage criteria.
2/2020 Annual review. No changes to coverage criteria.
2/2021 Annual review. No changes to coverage criteria.
1/2022 Annual review with no changes to coverage criteria. Updated background and
reference.
1/2023 Annual review with no changes to coverage criteria. Added state mandate and
updated references.
1/2024 Annual review. Revised duration of authorization.
1/2025 Annual review. Updated formatting without change to clinical intent.
© 2025 UnitedHealthcare Services, Inc.
2